{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"7","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"Measured form date of registration to date of first observation of progression disease, death due to any cause, symptomatic deterioration, or early discontinuation of treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received 1000 mg /m\\^2 of gemcitabine on Day 1 and 8 and 175 mg/m\\^2 of paclitaxel on Day 1 intravenously every 21 days for 6 cycles ( 1 cycle = 21 days)","id":"OG000","title":"Paclitaxel + Gemcitabine (Elderly Cohort: Age >= 70)"}],"paramType":"MEDIAN","populationDescription":"Eligible patients aged 70 years and older who had received any treatment were included in the analysis. Patients aged 60 years or younger who served as a younger reference group for the pharmacokinetic study were excluded from analysis.","reportingStatus":"POSTED","timeFrame":"0-5 years","title":"Progression-free Survival in Patients Aged 70 Years and Older","type":"SECONDARY","unitOfMeasure":"months"}